SCART : Phase I/II study of oral MEK inhibitor Selumetinib (AZD6244 Hyd-Sulphate) in Combination with Highly Active Anti-Retroviral Therapy (HAART) in AIDS-associated Kaposiâ€™s sarcoma (KS)

Billingham, Lucinda (Principal Investigator)

Cancer Research UK Clinical Trials Unit

Short title	SCART : Phase I/II study of oral MEK inhibitor Selumetinib (AZD6244 Hyd-Sulphate) in Combination with Highly Active Anti-Retroviral Therapy (HAART) in AIDS-associated Kaposiâ€™s sarcoma (KS)
Status	Finished
Effective start/end date	21/03/12 → 20/12/19

Funding

ASTRA ZENECA UK LIMITED

1 Article

Selumetinib in Combination with Anti Retroviral Therapy in HIV-associated Kaposi sarcoma (SCART): an open-label, multicentre, phase I/II trial
Young, R. J., Kirkham, A., Savage, J., Gaskell, C., Johnson, S., Dockrell, D. H., Bower, M., Westwell, S., Bowman, C., Leahy, M., Woll, P. & Billingham, L., 19 Mar 2025, In: BMC Cancer. 25, 1, 505.
Research output: Contribution to journal › Article › peer-review

Open Access
File
9 Downloads (Pure)